LLY•benzinga•
Eli Lilly & Co Announces Kisunla (Donanemab) Receives Marketing Authorization In Australia For The Treatment Of Early Symptomatic Alzheimer's Disease
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 21, 2025 by benzinga